Hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Investigator Initiated Study Promotion Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients who histologically or clinically diagnosed with HCC. 2 Patients who scheduled for systemic therapy for HCC. At the start of systemic therapy, other treatments (TACE, etc.) will not be used in combination. 3 20 years old or over. 4 Patients who obtained written informed consent of this clinical study.
Exclusion criteria
Exclusion criteria: 1 Patients with a past history of systemic therapy (including molecular targeted therapies, immune checkpoint inhibitors, investigational drugs). Patients with prior history of hepatectomy, local ablative therapy, TACE, and radiation therapy are not excluded. 2 Patients participating in clinical trials requiring some intervention, such as new agents. 3 Patients who are judged to be unsuitable to enroll in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival of each treatment regimen at each treatment line | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, overall response rate, disease control rate and time to treatment failure of each regimen at each treatment line Grade 3 or greater adverse events of each regimen at each treatment line Drug exposure (initial dose, duration of treatment and dose intensity, transition rate to next treatment) of each regimen at each treatment line | — |
Countries
Japan
Contacts
Public ContactShinji Itoh
Kyushu University Department of surgery and science, Graduate school of medical science
Outcome results
None listed